Shao Xijia, Hu Yuhong, Jia Hao, Song Jiangping
Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Curr Cardiol Rep. 2025 Jul 31;27(1):119. doi: 10.1007/s11886-025-02270-3.
The rapid development of digital therapeutics (DTx) presents opportunities for cardiovascular diseases (CVD) intervention. This review aims to summarize the technologies and applications of DTx in the field of cardiovascular healthcare. It seeks to identify how DTx can enhance the effectiveness and efficiency of cardiovascular healthcare RECENT FINDINGS: Given the absence of a universally accepted definition, this review categorizes DTx applications in CVD into three main areas with based on widely recognized DTx characteristics: extended reality (XR)-assisted therapeutics, digital pill systems (DPS), and evidence-based applications designed for smartphones or smartwatches. XR aids surgical planning and execution by creating anatomical digital twins and providing immersive environments to reduce patient anxiety. DPS leverages ingestible sensors to enhance medication adherence and monitor physiological data, while APPs focus on CVD prevention, cardiac rehabilitation, and symptom tracking. Integrating artificial intelligence into DTx enhances its potential, allowing personalized interventions and improved data analysis. Despite its promise, the field faces challenges such as high costs, technological accessibility, and the need for robust regulatory frameworks to ensure safety and efficacy. With continued technological innovation and improved access, DTx is expected to play a transformative role in cardiovascular healthcare, bridging gaps in prevention, treatment, and long-term management CHARACTERISTICS: extended reality (XR)-assisted therapeutics, digital pill systems (DPS), and evidence-based applications designed for smartphones or smartwatches. XR aids surgical planning and execution by creating anatomical digital twins and providing immersive environments to reduce patient anxiety. DPS leverages ingestible sensors to enhance medication adherence and monitor physiological data, while APPs focus on CVD prevention, cardiac rehabilitation, and symptom tracking. Integrating artificial intelligence into DTx enhances its potential, allowing personalized interventions and improved data analysis. Despite its promise, the field faces challenges such as high costs, technological accessibility, and the need for robust regulatory frameworks to ensure safety and efficacy. With continued technological innovation and improved access, DTx is expected to play a transformative role in cardiovascular healthcare, bridging gaps in prevention, treatment, and long-term management. DTx show promise in the prevention, intervention, and management of CVD. Despite existing challenges, technological advancements and regulatory improvements are expected to expand the role of DTx in cardiovascular healthcare.
数字疗法（DTx）的快速发展为心血管疾病（CVD）的干预带来了机遇。本综述旨在总结DTx在心血管医疗领域的技术和应用。它试图确定DTx如何提高心血管医疗的有效性和效率。最新发现：鉴于缺乏普遍接受的定义，本综述根据广泛认可的DTx特征将DTx在CVD中的应用分为三个主要领域：扩展现实（XR）辅助疗法、数字药丸系统（DPS）以及为智能手机或智能手表设计的循证应用。XR通过创建解剖数字孪生体并提供沉浸式环境来辅助手术规划和执行，以减轻患者焦虑。DPS利用可摄入传感器来提高药物依从性并监测生理数据，而应用程序则专注于CVD预防、心脏康复和症状跟踪。将人工智能集成到DTx中可增强其潜力，实现个性化干预并改进数据分析。尽管前景广阔，但该领域面临着成本高昂、技术可及性以及需要强大监管框架以确保安全性和有效性等挑战。随着技术的不断创新和可及性的提高，DTx有望在心血管医疗中发挥变革性作用，弥合预防、治疗和长期管理方面的差距。特点：扩展现实（XR）辅助疗法、数字药丸系统（DPS）以及为智能手机或智能手表设计的循证应用。XR通过创建解剖数字孪生体并提供沉浸式环境来辅助手术规划和执行，以减轻患者焦虑。DPS利用可摄入传感器来提高药物依从性并监测生理数据，而应用程序则专注于CVD预防、心脏康复和症状跟踪。将人工智能集成到DTx中可增强其潜力，实现个性化干预并改进数据分析。尽管前景广阔，但该领域面临着成本高昂、技术可及性以及需要强大监管框架以确保安全性和有效性等挑战。随着技术的不断创新和可及性的提高，DTx有望在心血管医疗中发挥变革性作用，弥合预防、治疗和长期管理方面的差距。DTx在CVD的预防、干预和管理方面显示出前景。尽管存在现有挑战，但技术进步和监管改进有望扩大DTx在心血管医疗中的作用。
